Clinical Trial Update: A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

Early Phase 1 dosimetry study of two Lutetium-177 radiopharmaceuticals (rhPSMA-10.1 and lutetium-177 vipivotide tetraxetan) in patients with non-curative metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lutetium-177 rhPSMA-10.1 (lutetium-177 rhPSMA-10.1)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Blue Earth Therapeutics Ltd | Conditions: Metastatic Prostate Cancer | EARLY_Phase 1 | Status: TERMINATED